Modified phages: novel antimicrobial agents to combat infectious diseases.

Biotechnol Adv

Department of Pharmaceutical Biotechnology and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.

Published: January 2012

Researchers increasingly believe that microbial, molecular and synthetic biology techniques along with genetic engineering will facilitate the treatment of persistent infectious diseases. However, such therapy has been plagued by the emergence of antibiotic-resistant bacteria, resulting in significant obstacles to treatment. Phage therapy is one promising alternative to antibiotics, especially now that recent modifications to ubiquitous phages have made them more controllable. Additionally, convincing in vitro and in vivo studies of genetically modified lytic phages and engineered non-lytic phages have confirmed the advantages of novel, specific bactericidal agents over antibiotics in some cases. There is still a need for a better understanding of phage therapy, however, before it can be adopted widely.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biotechadv.2011.06.003DOI Listing

Publication Analysis

Top Keywords

infectious diseases
8
phage therapy
8
modified phages
4
phages novel
4
novel antimicrobial
4
antimicrobial agents
4
agents combat
4
combat infectious
4
diseases researchers
4
researchers increasingly
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!